The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...
Acasunlimab is under clinical development by BioNTech and currently in Phase III for Non-Small Cell Lung Cancer.
BNT-325 is under clinical development by BioNTech and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase ...
The BioNTech SE ADR BNTX inched 0.42% higher to $115.79 Friday, on what proved to be an all-around great trading session for ...
Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.
The new $467 million includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023.
Geode Capital Management LLC trimmed its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 0.8% during the 3rd quarter, ...
BUCKSCO.Today on MSN1d
BioNTech Agrees to Pay $467M to Penn as Part of COVID-19 Vaccine Royalties SettlementUniversity of Pennsylvania will receive $467 million from BioNTech as part of a settlement in a lawsuit over COVID-19 vaccine ...
Morgan Stanley analyst Terence Flynn notes that BioNTech (BNTX) announced last week that it had reached a settlement agreement with the National Institutes of Health and University of Pennsylvania ...
GEN uncovers seven biopharma-related trends based on interviews with experts and other industry stakeholders, as well as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback